

# SmartPA Criteria Proposal

<b>Drug/Drug Class:</b>	Targeted Immune Modulators, Tumor Necrosis Factor (TNF) Inhibitors PDL Edit
<b>First Implementation Date:</b>	January 22, 2004
<b>Proposed Date:</b>	June 18, 2020
<b>Prepared For:</b>	MO HealthNet
<b>Prepared By:</b>	MO HealthNet/Conduent
<b>Criteria Status:</b>	<input checked="" type="checkbox"/> Existing Criteria <input type="checkbox"/> Revision of Existing Criteria <input type="checkbox"/> New Criteria

## Executive Summary

**Purpose:** The MO HealthNet Pharmacy Program will implement a state-specific preferred drug list.

**Why Issue Selected:** Tumor necrosis factor (TNF) inhibitors are agents that bind to the TNF alpha receptor and interfere with cytokine binding. The interference of TNF inhibits the cytokine driven inflammatory response and helps alleviate the symptoms of several auto-immune disorders, including rheumatoid arthritis, psoriasis, and ankylosing spondylitis. Although these agents interact with the same biological target and pathway, the structure and mechanism of action of these agents vary. TNF inhibitors have demonstrated equal efficacy to methotrexate (MTX) in treating rheumatoid arthritis and when TNF inhibitors and MTX are used in combination a greater level of efficacy is achieved than either achieves alone. There are currently 5 agents in this class, and while there is a great deal of overlap in their indications, there are also unique indications for each. Each agent is administered through either the subcutaneous route, intravenous route, or either route depending on the indication. These agents display a wide range of potentially serious adverse effects, including infusion reactions, neutropenia, infection, heart failure, malignancy, and the development of autoantibodies against the agent leading to decreased efficacy over time. The TNF inhibitors are commonly reserved for participants with moderate-to-severe disease after failure to control disease progression first line therapies

Total program savings for the PDL classes will be regularly reviewed.

**Program-Specific Information:**

Preferred Agents	Non-Preferred Agents
<ul style="list-style-type: none"> <li>• Enbrel®</li> <li>• Humira®</li> </ul>	<ul style="list-style-type: none"> <li>• Cimzia®</li> <li>• Inflectra®</li> <li>• Remicade®</li> <li>• Renflexis®</li> <li>• Simponi®</li> <li>• Simponi ARIA®</li> </ul>

**Type of Criteria:**  Increased risk of ADE  Preferred Drug List  
 Appropriate Indications  Clinical Edit

**Data Sources:**  Only Administrative Databases  Databases + Prescriber-Supplied

*SmartPA PDL Proposal Form*

© 2020 Conduent Business Services, LLC. All rights reserved. Conduent™ and Conduent Design™ are trademarks of Conduent Business Services, LLC in the United States and/or other countries.

Other company trademarks are also acknowledged.

## Setting & Population

- Drug class for review: Targeted Immune Modulators, Tumor Necrosis Factor (TNF) Inhibitors
- Age range: All appropriate MO HealthNet participants aged 18 years or older unless indicated otherwise

## Approval Criteria

- Failure to achieve desired therapeutic outcomes with trial on 2 preferred agents
  - Documented trial period of preferred agents **OR**
  - Documented ADE/ADR to preferred agents **AND**
- Documented diagnosis of rheumatoid arthritis:
  - Adequate therapeutic trial of methotrexate in the past 720 days **OR**
  - Contraindication to methotrexate therapy **OR**
- Documentation of appropriate diagnosis and participant age range for requested agent:

Generic	Brand	Indication
Adalimumab	Humira®	<ul style="list-style-type: none"> <li>• Ankylosing spondylitis</li> <li>• Crohn's disease (aged 6 or older)</li> <li>• Hidradenitis suppurativa</li> <li>• Plaque psoriasis</li> <li>• Polyarticular juvenile idiopathic arthritis (aged 2 or older)</li> <li>• Psoriatic arthritis</li> <li>• Rheumatoid arthritis</li> <li>• Ulcerative colitis</li> <li>• Uveitis</li> </ul>
Certolizumab Pegol	Cimzia®	<ul style="list-style-type: none"> <li>• Ankylosing spondylitis</li> <li>• Crohn's disease</li> <li>• Non-radiographic axial spondyloarthritis</li> <li>• Plaque psoriasis</li> <li>• Psoriatic arthritis</li> <li>• Rheumatoid arthritis</li> </ul>
Entanercept	Enbrel®	<ul style="list-style-type: none"> <li>• Ankylosing spondylitis</li> <li>• Plaque psoriasis (aged 4 or older)</li> <li>• Polyarticular juvenile idiopathic arthritis (aged 2 or older)</li> <li>• Psoriatic arthritis</li> <li>• Rheumatoid arthritis</li> </ul>
Golimumab	Simponi® Simponi ARIA®	<ul style="list-style-type: none"> <li>• Ankylosing spondylitis</li> <li>• Psoriatic arthritis</li> <li>• Rheumatoid arthritis</li> <li>• Ulcerative colitis</li> </ul>
Infliximab	Remicade® Inflectra® Renflexis®	<ul style="list-style-type: none"> <li>• Ankylosing spondylitis</li> <li>• Crohn's disease</li> <li>• Juvenile idiopathic arthritis (Remicade only – aged 4 or older)</li> <li>• Pediatric Crohn's disease (aged 6 or older)</li> <li>• Pediatric ulcerative colitis (Remicade only – aged 6 or older)</li> <li>• Plaque psoriasis</li> <li>• Psoriatic arthritis</li> <li>• Rheumatoid arthritis</li> <li>• Ulcerative colitis</li> </ul>

### SmartPA PDL Proposal Form

© 2020 Conduent Business Services, LLC. All rights reserved. Conduent™ and Conduent Design™ are trademarks of Conduent Business Services, LLC in the United States and/or other countries.

Other company trademarks are also acknowledged.

## Denial Criteria

- Lack of adequate trial on required preferred agents
- Therapy will be denied if no approval criteria are met

## Required Documentation

Laboratory Results:   
MedWatch Form:

Progress Notes:   
Other:

## Disposition of Edit

Denial: Exception Code "0160" (Preferred Drug List)  
Rule Type: PDL

## Default Approval Period

1 year

## References

1. Evidence-Based Medicine and Fiscal Analysis: "Targeted Immune Modulators: Tumor Necrosis Factor (TNF) Inhibitors – Therapeutic Class Review", Conduent Business Services, L.L.C., Richmond, VA; April 2020.
2. 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis, Singh et al. Arthritis Care & Research – DOI 10.1002/acr.22783
3. Evidence-Based Medicine Analysis: "Targeted Immune Modulators (Biologics – DMARDs)". UMKC-DIC; April 2020.
4. Humira [package insert]. North Chicago, IL: AbbVie Inc; 2020.
5. Cimzia [package insert]. Smyrna, GA: UCB Inc; 2019.
6. Enbrel [package insert]. Thousand Oaks, CA: Immunex Corporation; 2020.
7. Simponi [package insert]. Horsham, PA: Janssen Biotech, Inc; 2019.
8. Simponi Aria [package insert]. Horsham, PA: Janssen Biotech, Inc; 2019.
9. Remicade [package insert]. Horsham, PA: Janssen Biotech, Inc; 2020.
10. Renflexis [package insert]. Whitehouse Station, NJ: Merck Sharp & Dohme Corp; 2020.
11. Inflectra [package insert]. New York, NY: Pfizer; 2019.
12. Lippincott, Williams, Wilkins. PDR Electronic Library, Montvale NJ; 2020.
13. USPDI, Micromedex; 2020.
14. Facts and Comparisons eAnswers (online); 2020 Clinical Drug Information, LLC.

### SmartPA PDL Proposal Form

© 2020 Conduent Business Services, LLC. All rights reserved. Conduent™ and Conduent Design™ are trademarks of Conduent Business Services, LLC in the United States and/or other countries.

Other company trademarks are also acknowledged.